Teligent Inc. (NASDAQ:TLGT) fell 2.3% during mid-day trading on Tuesday . The company traded as low as $8.23 and last traded at $8.24, with a volume of 98,964 shares changing hands. The stock had previously closed at $8.43.

A number of brokerages recently issued reports on TLGT. TheStreet upgraded Teligent from a “sell” rating to a “hold” rating in a research note on Thursday, June 23rd. Zacks Investment Research cut Teligent from a “strong-buy” rating to a “hold” rating in a research note on Thursday, June 30th. Oppenheimer Holdings Inc. restated a “hold” rating on shares of Teligent in a research note on Tuesday, April 26th. Raymond James Financial Inc. began coverage on Teligent in a research note on Wednesday, June 22nd. They issued a “strong-buy” rating and a $11.00 price objective on the stock. Finally, JMP Securities began coverage on Teligent in a research note on Wednesday, June 29th. They issued a “hold” rating on the stock. Five analysts have rated the stock with a hold rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $9.42.

The company’s market cap is $437.21 million. The firm’s 50 day moving average is $7.28 and its 200 day moving average is $6.20.

Teligent (NASDAQ:TLGT) last released its quarterly earnings results on Thursday, April 28th. The company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.03) by $0.05. The firm had revenue of $15.70 million for the quarter, compared to analysts’ expectations of $14.33 million. The business’s quarterly revenue was up 46.7% compared to the same quarter last year.

An institutional investor recently bought a new position in Teligent stock. Russell Frank Co bought a new position in Teligent Inc. (NASDAQ:TLGT) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 410,606 shares of the company’s stock, valued at approximately $3,605,000. Russell Frank Co owned approximately 0.78% of Teligent at the end of the most recent quarter.

Teligent, Inc, formerly IGI Laboratories, Inc, is a specialty generic pharmaceutical company. The Company markets and sells generic injectable pharmaceutical products under its own label in the United States and Canada. It provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.